However, in this study, the prevalence of APOE ε4 carriers in AD and aMCI was 61.70 and 59.38%, respectively, which is similar to that of a previous study with large sample of Aβ biomarker positive individuals (66% in AD and 64% in MCI) (Mattsson et al., 2018). This evidence concerns the gene APOE and Alzheimer disease.